All
From Patient to Researcher: It’s Not All About the Cure
I’m working to make cancer treatments less painful by developing donor-derived CAR therapies, so others don’t have to suffer the way I did.
My Oncology Nurse Knows Me so Well
Patricia Chin, a registered nurse, forms meaningful bonds with patients, providing expert care, emotional support and kindness through cancer treatment.
Survivorship, the Hardest Part After Cancer?
Survivorship after cancer can be harder than treatment. My daughter faces lasting side effects, fear, and uncertainty while building a life she hopes to live fully.
Breaking Down the VERIFY Trial for Patients With Polycythemia Vera
Dr. Aaron Gerds breaks down the outcomes of the phase 3 VERIFY trial, investigating rusfertide, for patients with polycythemia vera, a type of blood cancer.
Similar Outcomes Yielded Between Surgery and Radiation in Low-Risk Prostate Cancer
Surgery and radiation yield similar cancer outcomes for low-risk prostate cancer, but higher-risk cases may require combining treatments, experts said.
Pancreatic Cancer Tried to Crash My Three Daughters’ Weddings
I was told I wouldn’t live to see my daughters’ weddings — but 12 years later, I’ve been there for two, and I’m holding out hope for the third.
Updates in Shared Decision-Making in Lung Cancer Following ASCO 2025
Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert oncologists.
FDA Grants Fast Track Designation to RAD101 in Brain Metastases
The FDA granted fast track designation to RAD101, an experimental imaging agent, to improve detection of recurrent brain metastases.
What Should Patients With Lung Cancer Know After ASCO 2025?
Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.
FDA Approves Perioperative Keytruda for Locally Advanced Head and Neck Cancer
Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care.
Beyond Treatment: How Support Groups Helped Me Embrace My New Normal
Joining support groups after cancer treatment helped me heal emotionally, connect with others who understood and embrace a new, meaningful normal.
Bringing Light to More Personalized Medicine in Lung Cancer After ASCO 2025
Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.
How Love Helped Me Overcome my Cancer Diagnosis
Facing two life-threatening diagnoses, I overcame fear of self-injections by leaning on love, encouragement and determination to save my life.
FDA Approves UGN-102 For Some With Bladder Cancer
The FDA has granted approval to UGN-102 for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.
Don’t Miss Your Shot: A Letter to My Newly Diagnosed Self
Eminem’s lyric about having “one shot” stayed with me, and writing this letter to my newly diagnosed self, reminds me how that mindset saved my life.
What Patients With Genitourinary Cancers Need to Know After ASCO 2025
Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.
FDA Approves Brukinsa Tablet For Various Blood Cancers
FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as capsules.
A New Therapeutic Approach May Make Waves in Kidney Cancer Treatment
Dr. Michael Serzan provides expert takeaways on treatment updates for patients with early-stage kidney cancer following the 2025 ASCO Meeting.
Being a Cancer Survivor is a Gift I Never Take for Granted
Being a cancer survivor for nine and a half years has taught me to live in the moment, to make those moments count.
What Patients With Genitourinary Cancers Should Know After ASCO 2025
Dr. Joshua K. Sabari sat down with Dr. Daniel V. Araujo to discuss topline takeaways from the 2025 ASCO Meeting across the realm of genitourinary oncology
FDA Approves Ibtrozi for ROS1+ Advanced Non-Small Cell Lung Cancer
The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Connected by Shared Experiences and What Cancer Can’t Take Away
Two people connect by sharing their experiences about taking care of their spouses who died from cancer, and the realization that sparked something more.
Rusfertide Reduces Phlebotomy Need, Improves Quality of Life in Polycythemia Vera
Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.
FDA Grants Priority Review to Zepzelca Combo for Small Cell Lung Cancer
FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.
How to Prepare for Self-Advocacy After a Cancer Diagnosis
Patients can prepare for self-advocacy by bringing personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner.
Oncology Nurse Amanda Snyder Turns Personal Experience Into Advocacy
Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.
Enhertu Combo May Offer Longer Control for HER2+ Breast Cancer
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
The LAURA Trial May Lead to a New Era of Care in Lung Cancer
Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell lung cancer.
A Letter to My 2009 Self, Newly Diagnosed With Breast Cancer
I survived breast cancer and medical trauma, but the road was brutal. Fifteen years later, I’m alive, scarred and still searching for peace.
Understanding Breast Cancer Biomarkers Drives Patient Treatment Decisions
Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2-negative disease.